Report Highlights
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Report Includes
- 15 data tables and 80 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
- Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
- Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.
Report Scope
This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.
The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.
An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.
The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).
The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | ||||||||||||||||||||||||||||||||
| Forecast period considered | 2022-2027 | ||||||||||||||||||||||||||||||||
| Base year market size | $7.8 billion | ||||||||||||||||||||||||||||||||
| Market size forecast | $15 billion | ||||||||||||||||||||||||||||||||
| Growth rate | CAGR of 11.5% for the forecast period of 2022-2027 | ||||||||||||||||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||||||||||||||||
| Segments covered | Cancer Site, Purpose of Analysis, Test Platform, Region | ||||||||||||||||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||||||||||||||||||
| Companies studied |
|
||||||||||||||||||||||||||||||||
Frequently Asked Questions (FAQs)
- Abbott
- Johnson & Johnson
- Novartis
- Roche
- Termo fisher
Analyst Credentials
Kalyani Kottapenta – Assistant Manager, Life Sciences
Kalyani Kottapenta is a research professional with nine years of experience in the life sciences and healthcare industry. Her expertise in qualitative and quantitative market information, including market dynamics like market sizing, advanced excel based market modeling, data analysis, forecasting, company share analysis, and competitive landscape assessment of the medical device industry, developing custom reports. She holds a master’s degree in Microbiology and a bachelor’s in Biotechnology and Chemistry.
- Diagnostics and Therapeutics for HIV: Global Markets (PHM058D)
- The Market for Minimally Invasive Medical Devices (HLC051J)
Related Reports
Oncology Diagnostics: Global Markets
The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.
Proteomics: Technologies and Global Markets
The global market for proteomic technologies was valued at $27.6 billion in 2024. It is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global Cell Line and Membrane Market
The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.
Human Microbiome-based Drugs and Diagnostics: Global Markets
The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.
Global Microbiome Sequencing Market
The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.
Proteomics: Technologies and Global Markets
The global market for proteomic technologies was valued at $27.6 billion in 2024. It is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
Top Trending Reports
Next-Generation Advanced Batteries: Global Markets
The global market for next-generation advanced batteries is estimated to grow from $1.5 billion in 2024 to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
Global Markets and Manufacturing Technologies for Protein Drugs
The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Report Highlights
The global market for next generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9% for the period of 2020-2025.
Report Includes
- 22 data tables and 74 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
- Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
- Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
- Details of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.
Report Highlights
BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.
Report Includes
- An overview of the global market for next generation cancer diagnostics and related technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Analyses of the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic).
- Examination of each technology format to determine its market status, impact on future market segments, and projected growth through the forecast period.
- Discussion on factors influencing the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses.
- Assessments of the major next generation formats that are likely to become commercialized within the next five years.
- Profiles of companies in the industry as well as a look at corporate alliances.
Report Highlights
The total global annual market for next generation cancer diagnostics was $776 million in 2010, and is growing at a compound annual growth rate (CAGR) of 47%, to reach a forecast market size of $5.3 billion in 2015.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More